Dr Lal Pathlabs — 360° view

Dr Lal Pathlabs, a company in the Healthcare Service Provider industry, reported revenue of ₹874 crore and net profit of ₹194 crore for the September 2026 quarter.

Dr Lal Pathlabs (NSE: LALPATHLAB) closed at ₹2,006.00 on 20 Nov 2026, up 28.3% over the past year. Its market capitalisation is ₹33,670 crore and it trades at 55.6 times earnings.

Share price
₹2,006.00 (20 Nov 2026)
Market cap
₹33,670 Cr (20 Nov 2026)
P/E
55.60 (20 Nov 2026)
Revenue
₹874 Cr (September 2026 quarter)
Net profit
₹194 Cr (September 2026 quarter)
ROCE
28.0% (FY26)
ROE
22.3% (FY26)
Book value
₹164 (FY26)
Dividend yield
0.87% (last 12 months to 20 Nov 2026)
52-week high / low
₹2,079.00 / ₹1,272.60 (20 Nov 2026)
1-year return
28.3% (to 20 Nov 2026)
Sector
Healthcare
Industry
Healthcare Service Provider
Symbol
NSE: LALPATHLAB

Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.